Pendopharm (Pharmascience’s division) has entered into an exclusive distribution agreement with Ascendis as per which the former will handle regulatory approval & commercialization of Ascendis’ TransCon PTH to treat hypoparathyroidism in Canada. Financial details were undisclosed
TransCon PTH (QD) is a prodrug of parathyroid hormone (PTH 1-34) intended to maintain normal PTH levels over 24hrs. It is being developed by Teijin in Japan & VISEN Pharmaceuticals in China
Additionally, Ascendis’ NDA of TransCon PTH for chronic hypoparathyroidism is under US FDA’s review with the decision anticipated on Aug 14, 2024. It was approved by the UK’s MHRA in Apr 2024 as well as by EC & EEA in Nov 2023 for the same indication
Ref: Pendopharm | Image: Pendopharm
Related News:- Ascendis Pharma Receives MHRA Approval for YORVIPATH (Palopegteriparatide) Against Chronic Hypoparathyroidism in Great Britain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
